The effect of COVID rehabilitation for ongoing symptoms Post HOSPitalisation with COVID-19 (PHOSP-R): protocol for a randomised parallel group controlled trial on behalf of the PHOSP consortium.
The effect of COVID rehabilitation for ongoing symptoms Post HOSPitalisation with COVID-19 (PHOSP-R): protocol for a randomised parallel group controlled trial on behalf of the PHOSP consortium.
复制标题
Covid-19与Covid-19（PHOSP-R）住院后持续症状的康复作用：代表PHOSP财团的随机平行组对照试验的方案。
DOI：
10.1186/s13063-023-07093-7
复制
发表时间：
2023-01-26
期刊：
影响因子：
2.5
通讯作者：
Singh, Sally J.
中科院分区：
文献类型：
--
作者：
Daynes, Enya;Baldwin, Molly;Greening, Neil J.;Yates, Thomas;Bishop, Nicolette C.;Mills, George;Roberts, Matthew;Hamrouni, Malik;Plekhanova, Tatiana;Vogiatzis, Ioannis;Echevarria, Carlos;Nathu, Rashmita;McAuley, Hamish J. C.;Latimer, Lorna;Glennie, Jennifer;Chambers, Francesca;Penfold, Ruth;Hume, Emily;Magaritis, Dimitrios;Alexiou, Charikleia;Potthoff, Sebastian;Hogg, Mitchell James;Haighton, Catherine;Nichol, Bethany;Leavy, Olivia C.;Richardson, Matthew;Elneima, Omer;Singapuri, Amisha;Sereno, Marco;Saunders, Ruth M.;Harris, Victoria C.;Nolan, Claire M.;Bolton, Charlotte;Houchen-Wolloff, Linzy;Harrison, Ewen M.;Lone, Nazir;Quint, Jennifer;Chalmers, James D.;Ho, Ling-Pei;Horsley, Alex;Marks, Michael;Poinasamy, Krisnah;Ramen, Betty;Wain, Louise V.;Brightling, Christopher;Man, William D. -C.;Evans, Rachael;Singh, Sally J.
许多因COVID-19住院的成年人有持续的症状，如疲劳，呼吸困难和脑雾，限制了日常活动。这些症状可持续2年以上。虽然有有限的对照研究干预措施，可以支持那些持续的症状，有一些承诺，在康复干预措施，改善功能和症状，无论是使用面对面或数字方法，但证据仍然有限，这些研究往往缺乏一个对照组。这是一项嵌套单盲、平行组、随机对照试验，在PHOSP-COVID研究中进行，对康复（面对面或数字）与常规护理进行了比较，并进行了嵌入式定性评价。本研究的目的是确定康复干预对运动能力，生活质量和呼吸困难和疲劳等症状的有效性。主要结果是在8周的干预阶段后进行的增量穿梭行走测试。次要结局包括功能、力量和症状的主观评估。血液炎症标志物和肌肉活检是探索性结果。干预持续八周，结合联合收割机滴定运动疗法，症状管理和教育，无论是在面对面的设置或通过数字平台（www.yourcovidrecovery.nhs.uk）提供。建议的样本量为159名参与者，数据将是意向治疗分析，比较康复（面对面或数字）与常规护理。作为PHOSP-COVID研究的一部分，约克郡和亨伯利兹西部研究NHS伦理委员会获得了伦理批准，该研究在ISRCTN试验注册处（ISRCTN 13293865）进行了前瞻性注册。结果将分发给利益相关者，包括患者和公众，并在适当的期刊上发表。本研究的优势和局限性·本方案采用两种干预措施来支持那些持续存在COVID-19症状的人·这是一项双中心平行组随机对照试验·该方案得到了患者和公众参与团体的支持，他们将症状和活动限制的治疗确定为首要任务。在线版本包含补充材料，可在10.1186/s13063-023-07093-7。
Many adults hospitalised with COVID-19 have persistent symptoms such as fatigue, breathlessness and brain fog that limit day-to-day activities. These symptoms can last over 2 years. Whilst there is limited controlled studies on interventions that can support those with ongoing symptoms, there has been some promise in rehabilitation interventions in improving function and symptoms either using face-to-face or digital methods, but evidence remains limited and these studies often lack a control group. This is a nested single-blind, parallel group, randomised control trial with embedded qualitative evaluation comparing rehabilitation (face-to-face or digital) to usual care and conducted within the PHOSP-COVID study. The aim of this study is to determine the effectiveness of rehabilitation interventions on exercise capacity, quality of life and symptoms such as breathlessness and fatigue. The primary outcome is the Incremental Shuttle Walking Test following the eight week intervention phase. Secondary outcomes include measures of function, strength and subjective assessment of symptoms. Blood inflammatory markers and muscle biopsies are an exploratory outcome. The interventions last eight weeks and combine symptom-titrated exercise therapy, symptom management and education delivered either in a face-to-face setting or through a digital platform (www.yourcovidrecovery.nhs.uk). The proposed sample size is 159 participants, and data will be intention-to-treat analyses comparing rehabilitation (face-to-face or digital) to usual care. Ethical approval was gained as part of the PHOSP-COVID study by Yorkshire and the Humber Leeds West Research NHS Ethics Committee, and the study was prospectively registered on the ISRCTN trial registry (ISRCTN13293865). Results will be disseminated to stakeholders, including patients and members of the public, and published in appropriate journals. Strengths and limitations of this study • This protocol utilises two interventions to support those with ongoing symptoms of COVID-19 • This is a two-centre parallel-group randomised controlled trial • The protocol has been supported by patient and public involvement groups who identified treatments of symptoms and activity limitation as a top priority The online version contains supplementary material available at 10.1186/s13063-023-07093-7.
登录
查看更多内容
DOI：
10.1016/s2213-2600(21)00383-0
发表时间：
2021-11
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Evans RA;McAuley H;Harrison EM;Shikotra A;Singapuri A;Sereno M;Elneima O;Docherty AB;Lone NI;Leavy OC;Daines L;Baillie JK;Brown JS;Chalder T;De Soyza A;Diar Bakerly N;Easom N;Geddes JR;Greening NJ;Hart N;Heaney LG;Heller S;Howard L;Hurst JR;Jacob J;Jenkins RG;Jolley C;Kerr S;Kon OM;Lewis K;Lord JM;McCann GP;Neubauer S;Openshaw PJM;Parekh D;Pfeffer P;Rahman NM;Raman B;Richardson M;Rowland M;Semple MG;Shah AM;Singh SJ;Sheikh A;Thomas D;Toshner M;Chalmers JD;Ho LP;Horsley A;Marks M;Poinasamy K;Wain LV;Brightling CE;PHOSP-COVID Collaborative Group
通讯作者：
PHOSP-COVID Collaborative Group
影响因子：
10
作者：
通讯作者：
--
影响因子：
2.8
作者：
Bedree, Helen;Sunnquist, Madison;Jason, Leonard A.
通讯作者：
Jason, Leonard A.
DOI：
10.1111/j.2517-6161.1995.tb02031.x
发表时间：
1995-01-01
影响因子：
5.8
作者：
BENJAMINI, Y;HOCHBERG, Y
通讯作者：
HOCHBERG, Y
影响因子：
10
作者：
Li J;Xia W;Zhan C;Liu S;Yin Z;Wang J;Chong Y;Zheng C;Fang X;Cheng W;Reinhardt JD
通讯作者：
Reinhardt JD